Persistent URL of this record https://hdl.handle.net/1887/100421
In Collections
This item can be found in the following collections:
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- All authors
- McInnes, I.B.; Mease, P.J.; Kirkham, B.; Kavanaugh, A.; Ritchlin, C.T.; Rahman, P.; Heijde, D. van der; Landewe, R.; Conaghan, P.G.; Gottlieb, A.B.; Richards, H.; Pricop, L.; Ligozio, G.; Patekar, M.; Mpofu, S.; FUTURE 2 Study Grp
- Date
- 2015-09-19
- Journal
- Lancet
- Volume
- 386
- Issue
- 9999
- Pages
- 1137 - 1146